Breaking News, Financial News

Financial Report: AMRI

Contract revenue up 8% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AMRI   3Q Revenues: $62.5 million (+3%) 3Q Loss: $8.6 million (earnings were $3.7 million 3Q13) YTD Revenues: $190.0 million (+6%) YTD Loss:  $1.4 million (earnings were $7.5 million YTD13) Comments: Contract revenue in the quarter was $57.5 million, up 8%. Royalty revenue was $5.0 million, down 35% as a result of lower product sales/royalties from Allegra products. Discovery and Development Services revenue was $18.0 million, down 7%. API and Drug Product services revenue was $29.7 million,...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters